RxDoctor Payments Data

Vikas Veeranna, MD

Cardiovascular Disease · Manchester, NHNPI 1467623686

Payments from drug & device makers

$564in general payments, 2019–2025

Across 6 payments — averaging $93.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$179
  • Abbott$150
  • Heartflow, Inc.$149
  • Johnson & Johnson$46
  • Lantheus Medical Imaging, Inc.$22
  • Philips North America LLC$18

What the payments were for

  • Food & beverage$51892%
  • Education$468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 35th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$125,056
Medicare patients
1,640
Services billed
2,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndaqelTafamidis Meglumine13$290,476
EliquisApixaban181$225,232
XareltoRivaroxaban49$52,985
FarxigaDapagliflozin Propanediol12$6,630
Metoprolol Succinate317$3,927
Atorvastatin Calcium241$2,356
Flecainide Acetate21$1,886
Rosuvastatin Calcium79$1,206
Isosorbide Mononitrate ErIsosorbide Mononitrate52$782
Potassium Chloride38$682
Amlodipine Besylate95$635
Losartan Potassium65$605
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$604
Ranolazine ErRanolazine13$502
Carvedilol60$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$46$52,98549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →